{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:21:05Z","timestamp":1791973265993,"version":"4.3.4"},"reference-count":128,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":1782,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR000001"],"award-info":[{"award-number":["UL1TR000001"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13311-018-0658-8","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T12:43:50Z","timestamp":1534941830000},"page":"995-1005","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"title":["Inclusion Body Myositis: Update on Pathogenesis and Treatment"],"prefix":"10.1016","volume":"15","author":[{"given":"Elie","family":"Naddaf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Barohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen M.","family":"Dimachkie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-018-0658-8_bib1","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/JND-160198","article-title":"A systematic review and meta-analysis of prevalence studies of sporadic inclusion body myositis","volume":"4","author":"Callan","year":"2017","journal-title":"J Neuromuscul Dis"},{"key":"10.1007\/s13311-018-0658-8_bib2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/mus.25686","article-title":"Burden of illness and healthcare resource use in United States patients with sporadic inclusion body myositis","volume":"56","author":"Capkun","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-0658-8_bib3","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.ncl.2014.04.001","article-title":"Inclusion body myositis","volume":"32","author":"Dimachkie","year":"2014","journal-title":"Neurol Clin"},{"issue":"Pt 3","key":"10.1007\/s13311-018-0658-8_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"key":"10.1007\/s13311-018-0658-8_bib5","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4065\/82.4.441","article-title":"Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients","volume":"82","author":"Oh","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.1007\/s13311-018-0658-8_bib6","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/mus.24689","article-title":"Camptocormia as presenting manifestation of a spectrum of myopathic disorders","volume":"52","author":"Ghosh","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-0658-8_bib7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mus.24060","article-title":"Inclusion-body myositis presenting with facial diplegia","volume":"49","author":"Ghosh","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-0658-8_bib8","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1212\/01.WNL.0000145834.17020.86","article-title":"Primary respiratory failure in inclusion body myositis","volume":"63","author":"Voermans","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004552","article-title":"A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis","volume":"4","author":"Brady","year":"2014","journal-title":"BMJ Open"},{"key":"10.1007\/s13311-018-0658-8_bib11","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1212\/01.WNL.0000033795.17156.00","article-title":"Diagnostic criteria for respiratory chain disorders in adults and children","volume":"59","author":"Bernier","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-018-0658-8_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-0658-8_bib14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/mus.21386","article-title":"Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis","volume":"40","author":"Salajegheh","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-0658-8_bib15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00401-009-0564-6","article-title":"p62\/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis","volume":"118","author":"Nogalska","year":"2009","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1007\/s13311-018-0658-8_bib16","first-page":"103","article-title":"Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis","volume":"30","author":"Dubourg","year":"2011","journal-title":"Acta Myol"},{"key":"10.1007\/s13311-018-0658-8_bib17","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC International Workshop: inclusion body myositis, 2\u20134 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-0658-8_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020266","article-title":"Autoantibodies against a 43 kDa muscle protein in inclusion body myositis","volume":"6","author":"Salajegheh","year":"2011","journal-title":"PLoS One"},{"key":"10.1007\/s13311-018-0658-8_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-018-0658-8_bib20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-018-0658-8_bib21","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ana.24919","article-title":"Pathomechanisms of anti-cytosolic 5\u2032-nucleotidase 1A autoantibodies in sporadic inclusion body myositis","volume":"81","author":"Tawara","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-018-0658-8_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/acr.22600","article-title":"Cytosolic 5\u2032-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases","volume":"68","author":"Lloyd","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1007\/s13311-018-0658-8_bib23","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/jnnp-2014-310008","article-title":"Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement","volume":"87","author":"Goyal","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1007\/s13311-018-0658-8_bib24","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2016-210282","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis","volume":"76","author":"Lilleker","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-018-0658-8_bib25","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5\u2032-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1007\/s13311-018-0658-8_bib26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/CND.0000000000000113","article-title":"Clinical and electrophysiological findings in hereditary inclusion body myopathy compared with sporadic inclusion body myositis","volume":"17","author":"Kazamel","year":"2016","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1007\/s13311-018-0658-8_bib27","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1212\/WNL.55.9.1385","article-title":"Epidemiology of inclusion body myositis in the Netherlands: a nationwide study","volume":"55","author":"Badrising","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"Inclusion body myositis","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-0658-8_bib29","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/mus.25036","article-title":"A protocol to develop clinical guidelines for inclusion-body myositis","volume":"53","author":"Jones","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-0658-8_bib31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/ana.410160207","article-title":"Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis","volume":"16","author":"Engel","year":"1984","journal-title":"Ann Neurol"},{"issue":"Pt 10","key":"10.1007\/s13311-018-0658-8_bib32","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/brain\/123.10.2030","article-title":"Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies","volume":"123","author":"Amemiya","year":"2000","journal-title":"Brain"},{"key":"10.1007\/s13311-018-0658-8_bib33","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1212\/01.wnl.0000265398.77681.09","article-title":"T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis","volume":"69","author":"Salajegheh","year":"2007","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jns.2008.12.024","article-title":"CCR7+ myeloid dendritic cells together with CCR7+ T cells and CCR7+ macrophages invade CCL19+ nonnecrotic muscle fibers in inclusion body myositis","volume":"279","author":"Tateyama","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-018-0658-8_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/mus.20649","article-title":"Myeloid dendritic cells in inclusion-body myositis and polymyositis","volume":"35","author":"Greenberg","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-0658-8_bib36","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1212\/01.wnl.0000187124.92826.20","article-title":"Plasma cells in muscle in inclusion body myositis and polymyositis","volume":"65","author":"Greenberg","year":"2005","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.4049\/jimmunol.178.1.547","article-title":"A local antigen-driven humoral response is present in the inflammatory myopathies","volume":"178","author":"Bradshaw","year":"2007","journal-title":"J Immunol"},{"key":"10.1007\/s13311-018-0658-8_bib38","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1212\/WNL.0000000000002291","article-title":"Hepatitis C virus infection in inclusion body myositis","volume":"86","author":"Uruha","year":"2016","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib39","first-page":"179","article-title":"Inclusion body myositis: series of 30 cases from a Brazilian tertiary center","volume":"38","author":"Alverne","year":"2013","journal-title":"Acta Reumatol Port"},{"issue":"Pt 6","key":"10.1007\/s13311-018-0658-8_bib40","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/brain\/119.6.1887","article-title":"Inclusion body myositis in HIV-1 and HTLV-1 infected patients","volume":"119","author":"Cupler","year":"1996","journal-title":"Brain"},{"key":"10.1007\/s13311-018-0658-8_bib41","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/ana.21103","article-title":"Inclusion body myositis with human immunodeficiency virus infection: four cases with clonal expansion of viral-specific T cells","volume":"61","author":"Dalakas","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-018-0658-8_bib42","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/brain\/aww024","article-title":"Association of inclusion body myositis with T cell large granular lymphocytic leukaemia","volume":"139","author":"Greenberg","year":"2016","journal-title":"Brain"},{"key":"10.1007\/s13311-018-0658-8_bib43","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.3324\/haematol.2009.018481","article-title":"Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases","volume":"95","author":"Bareau","year":"2010","journal-title":"Haematologica"},{"key":"10.1007\/s13311-018-0658-8_bib44","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/brain\/aww053","article-title":"Cytotoxic T cells go awry in inclusion body myositis","volume":"139","author":"Hohlfeld","year":"2016","journal-title":"Brain"},{"key":"10.1007\/s13311-018-0658-8_bib45","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/blood-2016-08-692590","article-title":"LGL leukemia: from pathogenesis to treatment","volume":"129","author":"Lamy","year":"2017","journal-title":"Blood"},{"key":"10.1007\/s13311-018-0658-8_bib46","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1750-3639.2001.tb00390.x","article-title":"Increased expression of the normal cellular isoform of prion protein in inclusion-body myositis, inflammatory myopathies and denervation atrophy","volume":"11","author":"Zanusso","year":"2001","journal-title":"Brain Pathol"},{"key":"10.1007\/s13311-018-0658-8_bib47","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/0140-6736(92)90388-J","article-title":"beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis","volume":"339","author":"Askanas","year":"1992","journal-title":"Lancet (London, England)"},{"key":"10.1007\/s13311-018-0658-8_bib48","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1001\/archneur.1991.00530240033013","article-title":"Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments","volume":"48","author":"Mendell","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1007\/s13311-018-0658-8_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2119\/molmed.2015.00168","article-title":"BACE-1, PS-1 and sAPP\u03b2 levels are increased in plasma from sporadic inclusion body myositis patients: surrogate biomarkers among inflammatory myopathies","volume":"21","author":"Catal\u00e1n-Garc\u00eda","year":"2015","journal-title":"Mol Med"},{"key":"10.1007\/s13311-018-0658-8_bib50","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00401-010-0737-3","article-title":"Novel demonstration of amyloid-\u03b2 oligomers in sporadic inclusion-body myositis muscle fibers","volume":"120","author":"Nogalska","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-018-0658-8_bib51","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00001756-199306000-00055","article-title":"beta-Amyloid precursor protein mRNA is increased in inclusion-body myositis muscle","volume":"4","author":"Sarkozi","year":"1993","journal-title":"Neuroreport"},{"key":"10.1007\/s13311-018-0658-8_bib52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00401-009-0554-8","article-title":"Increased plasma amyloid-beta42 protein in sporadic inclusion body myositis","volume":"118","author":"Abdo","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-018-0658-8_bib53","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/NEN.0000000000000196","article-title":"Activation of the unfolded protein response in sporadic inclusion-body myositis but not in hereditary GNE inclusion-body myopathy","volume":"74","author":"Nogalska","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1007\/s13311-018-0658-8_bib54","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1146\/annurev.biochem.78.081507.101607","article-title":"Recognition and processing of ubiquitin-protein conjugates by the proteasome","volume":"78","author":"Finley","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"10.1007\/s13311-018-0658-8_bib55","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0002-9440(10)62994-X","article-title":"Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers","volume":"167","author":"Fratta","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1007\/s13311-018-0658-8_bib56","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00687390","article-title":"Rimmed vacuoles","volume":"51","author":"Fukuhara","year":"1980","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-018-0658-8_bib57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.24847","article-title":"Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis","volume":"81","author":"G\u00fcttsches","year":"2017","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-018-0658-8_bib58","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4161\/auto.6.7.12785","article-title":"Quantitation of \u201cautophagic flux\u201d in mature skeletal muscle","volume":"6","author":"Ju","year":"2010","journal-title":"Autophagy"},{"key":"10.1007\/s13311-018-0658-8_bib59","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/hmg\/dds524","article-title":"mTOR dysfunction contributes to vacuolar pathology and weakness in valosin-containing protein associated inclusion body myopathy","volume":"22","author":"Ching","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-018-0658-8_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122888","article-title":"Rapamycin and chloroquine: the in vitro and in vivo effects of autophagy-modifying drugs show promising results in valosin containing protein multisystem proteinopathy","volume":"10","author":"Nalbandian","year":"2015","journal-title":"PLoS One"},{"key":"10.1007\/s13311-018-0658-8_bib61","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.2353\/ajpath.2010.100050","article-title":"Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers","volume":"177","author":"Nogalska","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1007\/s13311-018-0658-8_bib62","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4161\/auto.4245","article-title":"Macroautophagy as a pathomechanism in sporadic inclusion body myositis","volume":"3","author":"L\u00fcnemann","year":"2007","journal-title":"Autophagy"},{"key":"10.1007\/s13311-018-0658-8_bib63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00401-003-0774-2","article-title":"Expression of lysosome-related proteins and genes in the skeletal muscles of inclusion body myositis","volume":"107","author":"Kumamoto","year":"2004","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-018-0658-8_bib64","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1128\/MCB.24.18.8055-8068.2004","article-title":"Sequestosome 1\/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation","volume":"24","author":"Seibenhener","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1007\/s13311-018-0658-8_bib65","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.nmd.2016.12.009","article-title":"The role of p62\/SQSTM1 in sporadic inclusion body myositis","volume":"27","author":"Nakano","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-0658-8_bib66","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1101\/gad.13.10.1211","article-title":"Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls","volume":"13","author":"Kaufman","year":"1999","journal-title":"Genes Dev"},{"key":"10.1007\/s13311-018-0658-8_bib67","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1196\/annals.1391.032","article-title":"Heat shock proteins and protection of the nervous system","volume":"1113","author":"Brown","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1007\/s13311-018-0658-8_bib68","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/nan.12038","article-title":"Chaperone-mediated autophagy components are upregulated in sporadic inclusion-body myositis muscle fibres","volume":"39","author":"Cacciottolo","year":"2013","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1007\/s13311-018-0658-8_bib69","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/j.1471-4159.2006.03668.x","article-title":"Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers","volume":"96","author":"Nogalska","year":"2006","journal-title":"J Neurochem"},{"key":"10.1007\/s13311-018-0658-8_bib70","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1212\/WNL.54.5.1033","article-title":"AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis","volume":"54","author":"Banwell","year":"2000","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib71","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00401-005-1035-3","article-title":"Myostatin is increased and complexes with amyloid-\u03b2 within sporadic inclusion-body myositis muscle fibers","volume":"110","author":"W\u00f3jcik","year":"2005","journal-title":"Acta Neuropathol"},{"key":"10.1007\/s13311-018-0658-8_bib72","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.expneurol.2006.12.014","article-title":"Endoplasmic reticulum stress induces myostatin precursor protein and NF-\u03baB in cultured human muscle fibers: Relevance to inclusion body myositis","volume":"204","author":"Nogalska","year":"2007","journal-title":"Exp Neurol"},{"key":"10.1007\/s13311-018-0658-8_bib73","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-018-0997-9","article-title":"Endoplasmic reticulum stress induces myostatin high molecular weight aggregates and impairs mature myostatin secretion","author":"Sachdev","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1007\/s13311-018-0658-8_bib74","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.mco.0000134365.99523.7f","article-title":"Role of myostatin in metabolism","volume":"7","author":"Gonzalez-Cadavid","year":"2004","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1007\/s13311-018-0658-8_bib75","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1042\/CS20160080","article-title":"Mitochondrial DNA disturbances and deregulated expression of oxidative phosphorylation and mitochondrial fusion proteins in sporadic inclusion body myositis","volume":"130","author":"Catalan-Garcia","year":"2016","journal-title":"Clin Sci"},{"key":"10.1007\/s13311-018-0658-8_bib76","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1093\/nar\/gkw382","article-title":"Complex mitochondrial DNA rearrangements in individual cells from patients with sporadic inclusion body myositis","volume":"44","author":"Rygiel","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1007\/s13311-018-0658-8_bib77","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jaut.2016.08.004","article-title":"The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies","volume":"75","author":"Bhattarai","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1007\/s13311-018-0658-8_bib78","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ajpath.2013.06.003","article-title":"Overexpression of MHC class I in muscle of lymphocyte-deficient mice causes a severe myopathy with induction of the unfolded protein response","volume":"183","author":"Fr\u00e9ret","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1007\/s13311-018-0658-8_bib79","doi-asserted-by":"crossref","first-page":"331ra41","DOI":"10.1126\/scitranslmed.aad4583","article-title":"Targeting protein homeostasis in sporadic inclusion body myositis","volume":"8","author":"Ahmed","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-018-0658-8_bib80","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/brain\/awn053","article-title":"Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle","volume":"131","author":"Schmidt","year":"2008","journal-title":"Brain"},{"key":"10.1007\/s13311-018-0658-8_bib81","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0008-6363(02)00228-6","article-title":"Induction of iNOS expression in skeletal muscle by IL-1beta and NFkappaB activation: an in vitro and in vivo study","volume":"54","author":"Adams","year":"2002","journal-title":"Cardiovasc Res"},{"key":"10.1007\/s13311-018-0658-8_bib82","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/nan.12149","article-title":"Mitochondrial and inflammatory changes in sporadic inclusion body myositis","volume":"41","author":"Rygiel","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1007\/s13311-018-0658-8_bib83","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jneuroim.2012.04.007","article-title":"Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): a population control study","volume":"249","author":"Rojana-udomsart","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-018-0658-8_bib84","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/art.40045","article-title":"Immune-array analysis in sporadic inclusion body myositis reveals HLA-DRB1 amino acid heterogeneity across the myositis spectrum","volume":"69","author":"Rothwell","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1007\/s13311-018-0658-8_bib85","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.nmd.2009.07.015","article-title":"Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype","volume":"19","author":"Mastaglia","year":"2009","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-0658-8_bib86","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jneuroim.2012.05.003","article-title":"High-resolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypes","volume":"250","author":"Rojana-udomsart","year":"2012","journal-title":"J Neuroimmunol"},{"key":"10.1007\/s13311-018-0658-8_bib87","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.nmd.2014.12.009","article-title":"Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis","volume":"25","author":"Weihl","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-0658-8_bib88","doi-asserted-by":"crossref","first-page":"218.e1","DOI":"10.1016\/j.neurobiolaging.2016.07.024","article-title":"Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis","volume":"47","author":"Gang","year":"2016","journal-title":"Neurobiol Aging"},{"key":"10.1007\/s13311-018-0658-8_bib89","doi-asserted-by":"crossref","first-page":"1766.e1","DOI":"10.1016\/j.neurobiolaging.2014.12.039","article-title":"The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis","volume":"36","author":"Gang","year":"2015","journal-title":"Neurobiol Aging"},{"key":"10.1007\/s13311-018-0658-8_bib90","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.nmd.2013.09.008","article-title":"Polymorphism in the TOMM40 gene modifies the risk of developing sporadic inclusion body myositis and the age of onset of symptoms","volume":"23","author":"Mastaglia","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-0658-8_bib91","doi-asserted-by":"crossref","first-page":"13145","DOI":"10.1073\/pnas.0806192105","article-title":"The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae","volume":"105","author":"Hansson Petersen","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-018-0658-8_bib92","first-page":"3","article-title":"The LC3 interactome at a glance","volume":"127","author":"Wild","year":"2014","journal-title":"J Cell Sci"},{"key":"10.1007\/s13311-018-0658-8_bib93","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00005792-199307000-00002","article-title":"The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy","volume":"72","author":"Leff","year":"1993","journal-title":"Medicine (Baltimore)"},{"key":"10.1007\/s13311-018-0658-8_bib94","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1212\/WNL.44.8.1516","article-title":"Inclusion body myositis: treatment with intravenous immunoglobulin","volume":"44","author":"Amato","year":"1994","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib95","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib96","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s004150050005","article-title":"High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study","volume":"247","author":"Walter","year":"2000","journal-title":"J Neurol"},{"key":"10.1007\/s13311-018-0658-8_bib97","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1007\/s13311-018-0658-8_bib98","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.45.7.1302","article-title":"Inclusion body myositis: explanation for poor response to immunosuppressive therapy","volume":"45","author":"Barohn","year":"1995","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib99","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1212\/WNL.58.2.326","article-title":"Intravenous immunoglobulin for dysphagia of inclusion body myositis","volume":"58","author":"Cherin","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib100","first-page":"838","article-title":"Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients","volume":"30","author":"Dobloug","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1007\/s13311-018-0658-8_bib101","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","article-title":"Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis","volume":"57","year":"2001","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib102","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","article-title":"Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis","volume":"63","year":"2004","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib103","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","article-title":"Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study","volume":"61","author":"Lindberg","year":"2003","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib104","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1212\/01.wnl.0000192258.32408.54","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib105","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"key":"10.1007\/s13311-018-0658-8_bib106","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","article-title":"The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study","volume":"334","author":"Kosmidis","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-018-0658-8_bib107","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10072-011-0657-6","article-title":"Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis","volume":"32","author":"Sancricca","year":"2011","journal-title":"Neurol Sci"},{"key":"10.1007\/s13311-018-0658-8_bib108","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0006-291X(03)01254-3","article-title":"Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1","volume":"307","author":"Hargitai","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1007\/s13311-018-0658-8_bib109","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0361-9230(97)00118-4","article-title":"Bimoclomol (BRLP-42) ameliorates peripheral neuropathy in streptozotocin-induced diabetic rats","volume":"44","author":"B\u00edr\u00f3","year":"1997","journal-title":"Brain Res Bull"},{"key":"10.1007\/s13311-018-0658-8_bib110","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1212\/WNL.0000000000004960","article-title":"Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS","volume":"90","author":"Benatar","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib111","doi-asserted-by":"crossref","first-page":"355ra118","DOI":"10.1126\/scitranslmed.aad9823","article-title":"Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses","volume":"8","author":"Kirkegaard","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1007\/s13311-018-0658-8_bib112","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib113","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.cellbio.20.012103.135836","article-title":"Regulation of muscle mass by myostatin","volume":"20","author":"Lee","year":"2004","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1007\/s13311-018-0658-8_bib114","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","article-title":"Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes","volume":"25","author":"Mendell","year":"2017","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-018-0658-8_bib115","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.ymthe.2017.09.002","article-title":"Unfounded claims of improved functional outcomes attributed to follistatin gene therapy in inclusion body myositis","volume":"25","author":"Greenberg","year":"2017","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-018-0658-8_bib116","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","article-title":"A pilot randomized trial of oxandrolone in inclusion body myositis","volume":"58","author":"Rutkove","year":"2002","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib117","article-title":"Rapamycin for inclusion body myositis: targeting non-inflammatory mechanisms","author":"Lilleker","year":"2018","journal-title":"Rheumatology"},{"key":"10.1007\/s13311-018-0658-8_bib118","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/rheumatology\/ker292","article-title":"Safety and efficacy of exercise training in patients with an idiopathic inflammatory myopathy\u2014a systematic review","volume":"50","author":"Habers","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1007\/s13311-018-0658-8_bib119","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/16501970306110","article-title":"Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction","volume":"35","author":"Arnardottir","year":"2003","journal-title":"J Rehabil Med"},{"key":"10.1007\/s13311-018-0658-8_bib120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CND.0b013e3181a23c86","article-title":"Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis","volume":"10","author":"Johnson","year":"2009","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1007\/s13311-018-0658-8_bib121","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/(SICI)1097-4598(199710)20:10<1242::AID-MUS6>3.0.CO;2-C","article-title":"Safety and efficacy of strength training in patients with sporadic inclusion body myositis","volume":"20","author":"Spector","year":"1997","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-0658-8_bib122","doi-asserted-by":"crossref","first-page":"225","DOI":"10.5717\/jenb.2015.15090710","article-title":"Effects of long-term resistance exercise training on autophagy in rat skeletal muscle of chloroquine-induced sporadic inclusion body myositis","volume":"19","author":"Kwon","year":"2015","journal-title":"J Exerc Nutr Biochem"},{"key":"10.1007\/s13311-018-0658-8_bib123","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/PHM.0b013e31818a50e2","article-title":"Dysphagia in inclusion body myositis","volume":"87","author":"Oh","year":"2008","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1007\/s13311-018-0658-8_bib124","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jns.2017.07.031","article-title":"Botulinum toxin alleviates dysphagia of patients with inclusion body myositis","volume":"380","author":"Schrey","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1007\/s13311-018-0658-8_bib125","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00455-011-9384-7","article-title":"Pharyngeal dysphagia in inflammatory muscle diseases resulting from impaired suprahyoid musculature","volume":"27","author":"Claire Langdon","year":"2012","journal-title":"Dysphagia"},{"key":"10.1007\/s13311-018-0658-8_bib126","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.90.15_supplement.P3.437","article-title":"Circulatory Kv1.3+ cells in patients with sIBM","volume":"90","author":"Munoz","year":"2018","journal-title":"Neurology"},{"key":"10.1007\/s13311-018-0658-8_bib127","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/brain\/awr217","article-title":"A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities","volume":"134","author":"Cox","year":"2011","journal-title":"Brain"},{"key":"10.1007\/s13311-018-0658-8_bib128","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-018-0658-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0658-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0658-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T15:46:47Z","timestamp":1728661607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":128,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1878747923010279"],"URL":"https:\/\/doi.org\/10.1007\/s13311-018-0658-8","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inclusion Body Myositis: Update on Pathogenesis and Treatment","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-018-0658-8","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}